Trading Tech Stocks; Tech Stock News and daily Podcasts: January 2021

Thursday, January 28, 2021

#AIEye #Podcast 515: GBT (OTCPINK: $GTCH) Engages M2 to Help with qTerm FDA Approval, and C3.ai (NYSE: $AI) Announces General Availability of Ex Machina; #artificialintelligence

#AIEye #Podcast 515: GBT (OTCPINK: $GTCH) Engages M2 to Help with qTerm FDA Approval, and C3.ai (NYSE: $AI) Announces General Availability of Ex Machina; #artificialintelligence

#AI in Manufacturing to Reach $4.798 Billion by 2026

Point Roberts WA, Vancouver BC – January 28, 2021 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence – featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/012821-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/01282GTCH-AI.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (OTCPINK:GTCH) (NYSE:AI) (NYSE:ED)

GBT Technologies Inc. (OTC PINK:GTCH, has engaged M Squared Associates (M2) to assist with developing the FDA premarket strategy for its qTerm human vital signs device. According to the press release, M2 provides “a full range of regulatory, quality and clinical consulting services to US and international medical technology firms.” GBT’s CTO Danny Rittman said:

"We would like to bring our qTerm device to the highest standards within this domain and FDA clearance will demonstrate that the device is safe and effective for its intended use and confirm compliance with regulations and guidelines. Our objectives are to assure qTerm’s credibility as part of our plans for national commercialization. The technology is intended for personal and clinical use and will also be evaluated for remote telemedicine operation. Therefore, an extra focus will be on its cybersecurity system and protocol. The FDA review process will include evaluation of hardware and software systems, including functional verification and validation testing performance data. A comprehensive assessment of risks, data analysis, and cybersecurity requirements will be conducted. In addition, a thorough review of its development environment, revision history, and unresolved anomalies will be done according to FDA guidelines. qTerm device is a non-invasive device to measure human vitals and includes an intelligent analytics system. The FDA submission process is involved, with complex regulatory challenges that are typically associated with advanced technologies and therefore we decided to hire experts in the field."

For more on qTerm, and in particular on its FDA approval, check out a recent interview with Danny Rittman on the AI Eye:

https://www.investorideas.com/news/2021/artificial-intelligence/01271GTCH-qTerm.asp

C3.ai, Inc. (NYSE:AI) has announced the general availability of C3 AI Ex Machina, described in the press release as “a next-generation predictive analytics application that empowers anyone to develop, scale, and produce AI-based insights without writing code.” Chris Brownlee, Department Manager at Con Edison (NYSE:ED), whose data analysts use Ex Machina, commented:

"C3 AI Ex Machina empowers our analysts to easily harness all our data and assess reliability and safety risks. Our AMI Operations group recently used C3 AI Ex Machina to build predictive models that identified hazardous electric meters at risk of overheating. Using C3 AI Ex Machina, our business analysts are now able to evaluate near-real-time risk scores and immediately schedule prioritized field inspections. C3 AI Ex Machina has dramatically simplified and accelerated our ability to build and deploy machine learning models to address use cases that proactively identify risks and provide safer, more reliable service to our customers."

AI in Manufacturing to Reach $4.798 Billion by 2026

Research published by Valuates Reports finds that the global AI in Manufacturing market will grow from $840 million in 2019 to $4.798 billion by 2026 with a compound annual growth rate (CAGR) of 28.1 percent in the forecast period 2020-2026. An excerpt from the report’s press release outlines trends influencing the market’s growth:

The evolution of industrial IoT and automation is expected to drive the growth of artificial intelligence in the manufacturing market size. In the manufacturing sector, the Industrial Internet of Things (IIoT) plays a key role in implementing AI-based technology. By allowing an architecture that provides real-time information on operational and business systems, industrial IoT makes industrial processes efficient. The AI-based system takes less time and can operate without errors hence. Manufacturing performance is improving, which further contributes to business growth. Furthermore, the growing use of deep learning technology in the manufacturing industry is expected to drive the growth of the AI in manufacturing market size.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms. GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. GBT’s system envisions the creation of a global mesh network. The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Disclosure: GTCH is a paid monthly featured AI stock on Investorideas.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

The #AIEYE #Podcast - #Medtech #Stocks: GBT Technologies' (OTC: $GTCH) CTO Discusses the Significance of FDA Approval for the #qTerm Human Vital Signs Device; #artificialintelligence

The #AIEYE #Podcast - #Medtech #Stocks: GBT Technologies' (OTC: $GTCH) CTO Discusses the Significance of FDA Approval for the #qTerm Human Vital Signs Device; #artificialintelligence

Point Roberts WA, Vancouver BC – January 28, 2021 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye, featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/012521-GTCH-qTerm.mp3

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/01281GTCH-FDA-Approval-qTerm.asp

Hear the Ai Eye on Spotify

GBT Technologies Inc. (OTC PINK:GTCH) recently announced that GBT Tokenize Corp, its joint venture, is now seeking approval for its qTerm human vital signs device with the United States Food and Drug Administration (FDA). In an interview with Investorideas.com, GBT’s CTO, Danny Rittman, explained that the rigour of the FDA approval process was necessary and beneficial to the product.

“We are expecting some improvements and modifications because during the process of the FDA approval – and with their own guidelines and standards – we may definitely need to do some,” he said. “That’s something we’re looking forward to, because that’s only going to make the device better, more accurate and more credentialed. The more credentials we get for the device, the better for us. That’s the plan.”

FDA approval will also grant the qTerm legitimacy in the eyes of consumers, Rittman explained in a recent press release:

“Another aspect is to gain potential customer's confidence and trust in the product's performance and accuracy. We plan to offer the technology for personal, hospital and clinical usage [in] seeking to comply with the industry's standards and regulations.”

Rittman clarified however, that approval from the FDA is not essential but rather that the company was pursuing it to expand future market opportunities.

“FDA approval is not a must for qTerm, we voluntarily do this certification in order to bring the device to a clinical level which can open a whole world of possibilities marketing wise (clinics, hospitals, etc…),” he said. “The device can be introduced to the market as is in many other wearables that are not defined as a “medical device”, if for ramification only.”

In its first release, the qTerm will boast the abilities to measure body temperature, blood oxygen level and heart rate. GBT Tokenize will subsequently add blood pressure to this and these functions will be accompanied by a smartphone app and web application that will keep a history for the user's records, providing a geographical proximity alert and record statistical data about the user's vitals.

“In addition the device measures ambient temperatures to notify the user about an efficient measurement environment for accuracy purposes.” Rittman added.

While there are other mobile health detection devices out there, the qTerm is distinguished by its being powered by GBT’s AI technology. Rittman indicated in the press release:

“…we believe that its main advantage upon similar products is its Artificial Intelligence technology that offers advanced features like real-time health statistics, analytics, and monitoring.”

“The AI will basically collect the data, track it, keep a history and will alert personally, per person in case of abnormalities,” he said. “Assuming a person takes, on a daily basis, their blood pressure, oxygen level or heart rate … the AI engine will notice differences … and the user is going to get notifications.”

From the press release: “Early detection of potential health issues, based on vitals can be crucial and a life saver. Applying for an FDA clearance is a long process but we strongly believe it will bring our technology to the highest standards to be used by hospitals and individuals.”

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

About GBT Technologies Inc.

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclosure: GTCH is a paid for featured AI stock on Investorideas.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

#AI #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) Engaged M Squared Associates to Support #FDA 510(k) Submission for qTerm; #Artificialintelligence

#AI #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) Engaged M Squared Associates to Support #FDA 510(k) Submission for qTerm; #Artificialintelligence

SAN DIEGO - January 28, 2021 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company") announced today that GBT Tokenize Corp ("GBT/Tokenize") engaged M Squared Associates (M2) to assist with developing the FDA premarket strategy for its qTerm device. For more than 20 years, M2 has been providing a full range of regulatory, quality and clinical consulting services to US and international medical technology firms. M2 specializes in devices, biologics and combination products that are reviewed by FDA's Center for Devices and Radiological Health (CDRH).

Read this news featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01281M-Squared-Associates.asp

The process of filing for FDA clearance involves development of a sound regulatory strategy for pathway to market, including required preclinical and performance testing, software verification and validation activities and ensuring user needs are met. In addition, GBT/tokenize will partner with M2 to finalize technical design documentation, device labeling claims and intended use. Other aspects that will be evaluated include manufacturing processes, usability / human factors and the development of valid scientific evidence. The company will work with M2 to develop a detailed description of the device’s software and algorithm training requirements, including design specifications. qTerm computer program will be reviewed for its control functions and other required performance testing plans and criteria according to FDA guidance documentation.

qTerm is a human vitals device that is aimed to measure human vitals with a touch of a finger. The device received its Trademark allowance notice and will present it on the product/package as required by the United States Patent Office ("USPTO"). qTerm device is designed to work with a smartphone app and web application that will keep a history for the user's records, provide a geographical proximity alert and record statistical data about the user's vitals. The device will be empowered by an AI system for data analytics, proximity alerts and personal health management. qTerm will also be evaluated to work within remote telemedicine infrastructure and therefore an extra attention will be done for its cybersecurity system.

Therefore, an extra focus will be on its cybersecurity system and protocol. FDA review process will include evaluation of hardware and software systems, including functional verification and validation testing performance data. A comprehensive assessment of risks, data analysis, and cybersecurity requirements will be conducted. In addition, a thorough review of its development environment, revision history, and unresolved anomalies will be done according to FDA guidelines. qTerm device is a non-invasive device to measure human vitals and includes an intelligent analytics system. The FDA submission process is involved, with complex regulatory challenges that are typically associated with advanced technologies and therefore we decided to hire experts in the field." Stated Danny Rittman, the Company’s CTO.

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) ("GBT") (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT's mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT's goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT's vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

Get News Alerts on GBT Technologies Inc GTCH

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Get more tech stocks investor ideas- news, articles, podcasts and stock directories

Wednesday, January 27, 2021

#AIEye #Podcast: GBT Technologies’ (OTC: $GTCH) CTO Discusses the Significance of #FDA Approval for the #qTerm Human Vital Signs Device; #Artificialintelligence

#AIEye #Podcast: GBT Technologies’ (OTC: $GTCH) CTO Discusses the Significance of #FDA Approval for the #qTerm Human Vital Signs Device; #Artificialintelligence

Point Roberts WA, Vancouver BC – January 27, 2021 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye, featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/012521-GTCH-qTerm.mp3

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/01271GTCH-qTerm.asp

Hear the Ai Eye on Spotify

FDA approval will also grant the qTerm legitimacy in the eyes of consumers, Rittman explained in a recent press release:

Rittman clarified however, that approval from the FDA is not essential but rather that the company was pursuing it to expand future market opportunities.

“In addition the device measures ambient temperatures to notify the user about an efficient measurement environment for accuracy purposes.” Rittman added.

While there are other mobile health detection devices out there, the qTerm is distinguished by its being powered by GBT’s AI technology. Rittman indicated in the press release:

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

About GBT Technologies Inc.

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclosure: GTCH is a paid for featured AI stock on Investorideas.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

About Investorideas.com

About Investorideas.com - Big Investing Ideas Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Discclaimer /disclosure

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Investorideas.com breaking new for AI and tech stocks

Thursday, January 28, 2021

#AIEye #Podcast 515: GBT (OTCPINK: $GTCH) Engages M2 to Help with qTerm FDA Approval, and C3.ai (NYSE: $AI) Announces General Availability of Ex Machina; #artificialintelligence

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

The #AIEYE #Podcast - #Medtech #Stocks: GBT Technologies' (OTC: $GTCH) CTO Discusses the Significance of FDA Approval for the #qTerm Human Vital Signs Device; #artificialintelligence

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.

#AI #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) Engaged M Squared Associates to Support #FDA 510(k) Submission for qTerm; #Artificialintelligence

Wednesday, January 27, 2021

#AIEye #Podcast: GBT Technologies’ (OTC: $GTCH) CTO Discusses the Significance of #FDA Approval for the #qTerm Human Vital Signs Device; #Artificialintelligence

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash and others.